Efficacy and safety of guselkumab,an anti-interleukin-23 monoclonal antibody,compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III,double-blinded,placebo- and active comparator–controlled VOYAGE 1 trial 期刊界 All Journals 搜尽天下杂志传播学术成果专业期刊搜索期刊信息化学术搜索

Efficacy and safety of guselkumab,an anti-interleukin-23 monoclonal antibody,compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III,double-blinded,placebo- and active comparator–controlled VOYAGE 1 trial

摘要：
本文献已被 ScienceDirect 等数据库收录！